Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha

Neoplasma

Volumn 52, Issue 1, 2005, Pages 63-67

  Tothova E ^a   Kafkova A ^a   Fricova M ^a   Benova B ^a   Kirschnerova G ^b   Tothova A ^b  

^a Med Faculty of Safarik University   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Imatinib mesylate

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DEPRESSION; DIARRHEA; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; MALE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; SIDE EFFECT; SPLENOMEGALY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; XEROSTOMIA;

EID: 14744279180     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BONIFAZI F, DE VIVO A, GIANANTONIO R. Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
2. BRAZIEL RM, LAUNDER TM, DRUKER BJ, OLSON SB, MAGENIS RE et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia: 14 month's experience. Blood 2002; 100: 435-441.
3. CORTES J, O'BRIEN S, TALPAZ M. Clinical significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate therapy: Low levels of residual disease predict for response duration. Blood 2003; 102: 416a.
4. DRUKER BJ, LYDON NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3-7.
5. DRUKER BJ, TALPAZ M, RESTA DJ, PENG B, BUCHDUNGER E et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
6. FADERL S, TALPAZ M, ESTROV Z, KANTARJIAN HM. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med 1999; 131: 207-219.
7. GARCIA-MANERO G, FADERL S, O'BRIEN S. Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer 2003; 98: 437-457.
8. GILES FJ, KANTARJIAN HM, O'BRIEN S. Results of therapy with interferon α and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma 2001; 41: 309-319.
9. GOLDMAN JM, DRUKER BJ. Chronic myeloid leukemia: Current treatment options. Blood 2001; 98: 2039-242.
10. GRATWOHL A, BALDOMERO H, URBANO-ISPISUA A. Transplantation in chronic myeloid leukemia. Lancet 2002; 359: 712-713.
11. GUILHOT F, CHASTANG C, MICHALLET M, GUERCI A, HAROUSSEAU JL et al. Interferon alone alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 1997; 337: 223-229.
12. HOCHHAUS A, LAHAYE T, KREIL S. Interim analysis of imatinib treatment in patients with chronic myelogenous leukemia (CML): Evaluation of response and resistance. Proceedings ASCO 21, 2002; 262a.
13. KANTARJIAN HM, TALPAZ M, O'BRIEN S. Imatinib mesylate for Philadelphia choromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: Follow-up results. Clin Cancer Res 2002; 8: 2177-2187.
14. KANTARJIAN HM, SAWYERS C, HOCHHAUS A, GUILHOT F, SCHIFFER C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
15. KANTARJIAN HM, O'BRIEN S, CORTES J, SHAN J, GILES FJ et al. Complete cytogenetic and molecular responses to interferon-α based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-1041.
16. KANTARJIAN HM, O'BRIEN S, CORTES S GILES F, SHAN J et al. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004; 10: 68-75.
17. MAHON FX, DELBREI X, CONY-MAKHOUL P, FABERES C, BOIRON JM et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alpha. J Clin Oncol 2002; 20: 214-220.
18. MARIN D, MARKTEL S, SZYDLO R, KLEIN JP, BUA M et al. Survival of patients with chronic-phase chronic myeloid leukemia on imatinib after failure on interferon alpha. Lancet 2003; 362: 617-619.
19. MEDINA J, KANTARJIAN HM, TALPAZ M, O'BRIEN S, GARCIA-MANERO G et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003; 98: 1905-1911.
20. MERX K, MULLER MC, KREIL S, LAHAYE T, PASCHKA P et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002; 16: 1579-1583.
21. O'BRIEN S, GUILHOT F, LARSON R. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
22. SACCHI S, KANTARJIAN HM, O'BRIEN S. Long-term follow-up results of α-interferon based regiments in patients with late chronic phase chronic myelogenous leukemia. Leukemia 1997; 11: 1610-1616.
23. SAWYERS C, HOCHHAUS A, FELDMAN E, GOLDMAN JM, MILLER CB et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia: Results of a phase II study. Blood 2002; 99: 3530-3539.
24. TÓTHOVÁ E, KAFKOVÁ A, ŠTECOVÁ N, FRIČOVÁ M, GUMAN T, ŠVORCOVÁ E. Immune-mediated complications during interferon alpha therapy in chronic myelogenous leukemia. Neoplasma 2002; 49(2): 91-94.
25. WEISBERG E, GRIFFIN JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL-transformed hematopoietic cell lines: Blood 2000; 95: 3498-3505.